Novartis wins EU approval for CAR-T therapy

Novartis announced that the European Commission has approved Kymriah for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news